IL196643A0 - Methods and tools for the therapy of neurodegenerative pathologies - Google Patents
Methods and tools for the therapy of neurodegenerative pathologiesInfo
- Publication number
- IL196643A0 IL196643A0 IL196643A IL19664309A IL196643A0 IL 196643 A0 IL196643 A0 IL 196643A0 IL 196643 A IL196643 A IL 196643A IL 19664309 A IL19664309 A IL 19664309A IL 196643 A0 IL196643 A0 IL 196643A0
- Authority
- IL
- Israel
- Prior art keywords
- therapy
- tools
- methods
- neurodegenerative pathologies
- pathologies
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0606698A FR2904113A1 (en) | 2006-07-21 | 2006-07-21 | METHODS AND TOOLS FOR THERAPY OF NEURODEGENERATIVE PATHOLOGIES |
| PCT/FR2007/051706 WO2008009868A2 (en) | 2006-07-21 | 2007-07-20 | Methods and tools for the therapy of neurodegenerative pathologies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL196643A0 true IL196643A0 (en) | 2009-11-18 |
Family
ID=37736076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL196643A IL196643A0 (en) | 2006-07-21 | 2009-01-21 | Methods and tools for the therapy of neurodegenerative pathologies |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090317842A1 (en) |
| EP (1) | EP2047277A2 (en) |
| JP (1) | JP2009544964A (en) |
| KR (1) | KR20090086386A (en) |
| CN (1) | CN101542289A (en) |
| AU (1) | AU2007274872A1 (en) |
| CA (1) | CA2658464A1 (en) |
| FR (1) | FR2904113A1 (en) |
| IL (1) | IL196643A0 (en) |
| WO (1) | WO2008009868A2 (en) |
| ZA (1) | ZA200901094B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010046332A1 (en) * | 2008-10-20 | 2010-04-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for detecting soluble amyloid precursor protein (app) alpha and/or soluble app beta |
| WO2018015296A1 (en) * | 2016-07-20 | 2018-01-25 | Vib Vzw | Therapeutic agents for neurological and psychiatric disorders |
| JP6405549B2 (en) * | 2016-12-22 | 2018-10-17 | 国立研究開発法人理化学研究所 | Acute coronary syndrome marker and its use |
| EP3628315A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases |
| EP3628660A1 (en) | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8702338A (en) * | 1987-09-30 | 1989-04-17 | Mathilde Elisabeth Boon En Lan | METHOD FOR PROCESSING OF (BIO-) CHEMICAL OR (MICRO-) BIOLOGICAL REACTIONS USING MICRO-WAVES, METHODS AND APPARATUS THEREFOR |
| US5843794A (en) * | 1992-03-26 | 1998-12-01 | Montefiore Medical Center | Technique for the prevention of false positive reactions in immunological testing due to C1 and C1q components of the complement and method for screening for rheumatic factor |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| DE50103881D1 (en) * | 2001-06-12 | 2004-11-04 | Wiltfang Jens | Monoclonal antibody, mbAb 1E8, which is specific for the first two N-terminal amino acids of amyloid beta peptides and its use for the detection of amyloid beta peptides and / or sAPPa |
| GB0207249D0 (en) * | 2002-03-27 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
-
2006
- 2006-07-21 FR FR0606698A patent/FR2904113A1/en not_active Withdrawn
-
2007
- 2007-07-20 JP JP2009521315A patent/JP2009544964A/en active Pending
- 2007-07-20 KR KR1020097003519A patent/KR20090086386A/en not_active Withdrawn
- 2007-07-20 CA CA002658464A patent/CA2658464A1/en not_active Abandoned
- 2007-07-20 CN CNA2007800340073A patent/CN101542289A/en active Pending
- 2007-07-20 US US12/309,492 patent/US20090317842A1/en not_active Abandoned
- 2007-07-20 AU AU2007274872A patent/AU2007274872A1/en not_active Abandoned
- 2007-07-20 WO PCT/FR2007/051706 patent/WO2008009868A2/en not_active Ceased
- 2007-07-20 EP EP07823624A patent/EP2047277A2/en not_active Withdrawn
-
2009
- 2009-01-21 IL IL196643A patent/IL196643A0/en unknown
- 2009-02-16 ZA ZA200901094A patent/ZA200901094B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008009868A3 (en) | 2008-05-08 |
| US20090317842A1 (en) | 2009-12-24 |
| KR20090086386A (en) | 2009-08-12 |
| AU2007274872A1 (en) | 2008-01-24 |
| CA2658464A1 (en) | 2008-01-24 |
| FR2904113A1 (en) | 2008-01-25 |
| EP2047277A2 (en) | 2009-04-15 |
| CN101542289A (en) | 2009-09-23 |
| WO2008009868A2 (en) | 2008-01-24 |
| ZA200901094B (en) | 2010-01-27 |
| JP2009544964A (en) | 2009-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL196559A0 (en) | Combination therapy | |
| GB0614947D0 (en) | Epitope reduction therapy | |
| GB0718972D0 (en) | Compounds and methods of making the compounds | |
| GB0609492D0 (en) | Therapeutic agents | |
| HUE054365T2 (en) | Boronophthalides for therapeutic use | |
| GB0608928D0 (en) | Therapeutic agents | |
| GB0601962D0 (en) | Therapeutic agents | |
| IL196556A0 (en) | Combination therapy | |
| EP2054061A4 (en) | Combination therapy | |
| ZA200807884B (en) | Milling apparatus | |
| GB0616214D0 (en) | Therapeutic Agents | |
| PL2601972T3 (en) | Non-lithotripsic kidney-stone therapy | |
| ZA200902203B (en) | Combination therapy | |
| ZA200901094B (en) | Methods and tools for the therapy of neurodegenerative pathologies | |
| GB0611152D0 (en) | Therapeutic agents | |
| GB0607946D0 (en) | Mono and combination therapy | |
| GB0620818D0 (en) | Therapeutic agents | |
| GB0607949D0 (en) | Mono and combination therapy | |
| IL226363A0 (en) | Compounds and methods for the treatment of cancer | |
| GB0620059D0 (en) | Therapeutic agents | |
| GB0609676D0 (en) | Therapeutic agents | |
| ZA200807678B (en) | Meridamycin analogues for the treatment of neurodegenerative disorders | |
| HK1131205A (en) | Methods and tools for the therapy of neurodegenerative pathologies | |
| GB0607153D0 (en) | Therapeutic Method | |
| GB0622195D0 (en) | Therapeutic agents |